Just so good to see PMR on the plenary stage at #ACR22, after #EULAR2022 too SAPHYR study: sarilumab allows for - a quicker steroid wean & less toxicity - but also far more disease remission, quicker symptom resolution, better quality of life Game-changing. ABST1676 @RheumNow https://t.co/ZVqlMNoniu https://t.co/Fv3VRZrKGe

• https://twitter.com/drdavidliew/status/1533040378386993153

Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz

Intersting discussion post Plenary this AM - Agree w/RS that we should taper steroid - Is there a disease modifying benefit? I think not - When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred #ACR22 @RheumNow https://t.co/ylGXk2sca7

• https://twitter.com/EBRheum/status/1591864082705129472

Study shows no progressive increase of MRI structural lesions in SI joints of health individuals with increasing age, including: Bone marrow edema, erosions, fat lesions Abs#2258 @RheumNow #ACR22 https://t.co/W2dkRCAPc4

SSc and DM/PM can cause disease related sexual dysfunction ➡️ consider pelvic floor PT Abstract #0940 #ACR22 @RheumNow 🧘‍♀️8 week PT program targeting pelvic floor exercises and MSK issues impacting sexual function 🧘Women experienced sig. improved sexual function and QOL

Ab1677 #ACR22 by @MaxKonigMD Chimeric autoAg T cell recepter (CATCR) reprogram T cells to selectively kill autoreactive B cells Model CATCR for APLS via B2GPI-CATCR T-cells eliminating anti-B2GP DI B cells, dose-dependent Model for SELECTIVE Rx in APLS/rheum disease @RheumNow https://t.co/jMpMu10phL

Very cool preclinical plenary @MaxKonigMD Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells) Early days but super interesting possibilities - APS, SLE, AAV, & more? #ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9

#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow

Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i

• In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity…

Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies: precision cellular therapy selectively deplete autoreactive B cells @MaxKonigMD in the plenary: CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells #ACR22 @RheumNow https://t.co/5ZLocrwqKY

GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently. @RheumNow #ACR22 #Plenary

#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow

Great moderating PMR talk w/@SattuiSEMD this AM; phenomenal slides @drceowen re:imaging in PMR Big ?s: -Who needs this? All/some/many -Which modality? Nice summary slide -How to treat "subclinical" GCA (risk of overtreatment imo) Ideas for next year? #ACR22 @rheumnow #ACRBest https://t.co/akvsud3YVO

Preterm delivery and HTN disorders in #vasculitis Abstract #0953 #ACR22 @RheumNow @StanfordRheum 🤰87 deliveries from 1991-2012 🤰Higher risk for preterm delivery (PTD) (RR 4), PPROM (RR 4), HTN dx of preg. (RR 3) 🤰Of spon. PTD, 17% born between 20-31 weeks